A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

General Inclusion Criteria for ADAPT: * Female patients, age at diagnosis 18 years and above (consider patients at 70 years and above for ADAPT Elderly) * Candidate for chemotherapy on the basis of conventional criteria * Histologically confirmed unilateral primary invasive carcinoma of the breast * Clinical T1 - T4a-c * All clinical N (cN) * No clinical evidence for distant metastasis (M0) * Known HR status and HER2 status (local pathology) * Tumor block available for central pathology review * Performance Status ECOG \<= 1 or KI \>= 80% * Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements * The patient must be accessible for treatment and follow-up * Patients must qualify for neoadjuvant treatment * LVEF \> 50%; LVEF within normal limits of each institution measured by echocardiography and normal ECG (within 42 days prior to chemotherapy) * Laboratory requirements : * Leucocytes ≥ 3.5 x 109/L * Platelets ≥ 100 x 109/L * Hemoglobin ≥ 10 g/dL * Total bilirubin ≤ 1 x ULN * ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 x UNL * Creatinine ≤ 175 µmol/L (2 mg/dl) Additional inclusion criteria ADAPT Elderly: * ≥ 70 years old * Charlson scale ≤ 2 * HR+/HER2- disease: if RS and sequential testing are available N0-1/RS 12-25/poor response or N0-1/RS ≥26 * All G3 with Ki-67 ≥40% in tumors…